Overview

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (

Status:
Not yet recruiting

Trial end date:
2030-12-24

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of oral azacitidine in participants with low to intermediate International Prognostic Scoring System Revised (IPSS-R) myelodysplastic syndrome (MDS).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Azacitidine